Selection of 2 products from
£0.49 to £0.89
Estimated dispatch within 24 working hours.
Estimated dispatch within 24 working hours.
Carprodyl Quadri 120 mg chewable tablets for dogs
Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK)
One tablet contains:
Carprofen ....................................................... 120 mg
For the full list of excipients, see section 6.1.
Clover-shaped scored beige tablet
The tablet can be divided into four equal parts.
In the dog:
Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease.
As a follow-up to parenteral analgesia in the management of post-operative pain.
Do not use in pregnant and lactating bitches.
Do not use in dogs aged less than 4 months in the absence of specific data.
Do not use in cats.
Do not use in dogs, suffering from cardiac, hepatic or renal disease, when there is a possibility of gastrointestinal ulceration or bleeding or where there is evidence of blood dyscrasia.
Do not use in case of hypersensitivity to the active substance, to other NSAID and to any of the excipients.
See sections 4.3 and 4.5.
Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided. NSAID can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
As with other NSAID, photodermatitis during treatment with carprofen has been observed in laboratory animals and in humans. These skin reactions have never been observed in dogs.
Do not administer other NSAID concurrently or within 24 hours of each other. Some NSAID may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Due to the good palatability of the tablet, they should be stored in a safe place out of the reach of animals. Intake of dose exceeding the recommended number of tablets may lead to severe adverse effects. If this is the case, seek veterinary assistance immediately.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet to the physician. Wash hands after handling the product.
Typical undesirable effects associated with NSAID, such as vomiting, soft faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
As with other NSAID there is a risk of rare renal or idiosyncratic hepatic adverse events.
Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches. For breeding animals, do not use during reproduction period.
Carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can increase their respective toxic effects.
Do not use this veterinary medicinal drug concurrently with other NSAID or with glucocorticoids.
Concurrent administration of potentially nephrotoxic drugs (e.g. aminogylcoside antibiotics) should be avoided.
Refers also to section 4.5
For oral administration.
4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose. The analgesic effect from each dose persists for at least 12 hours.
The daily dose may be reduced, subject to clinical response.
Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.
To extend analgesic and anti-inflammatory cover post-operatively parenteral preoperative treatment with an injectable carprofen may be followed with carprofen tablets at 4 mg/kg/day for 5 days. Do not exceed the stated dose.
Tablets can be broken as follows: Put the tablet on a flat surface, with its scored side facing the surface (convex face up).
With the tip of forefinger, exert a slight vertical pressure on the middle of the tablet to break it into halves. In order to obtain quarters, then exert a slight pressure on the middle of one half with forefinger.
Each chewable tablet can be quartered for accurate dosing according to the individual body weight of the animal.
Number of tablets per day
Dog weight (kg)
The chewable tablets are flavoured and are accepted by dogs. The chewable tablets can be administered with or without food.
Bibliographic data report that carprofen is well tolerated in dogs at twice the recommended dosage for 42 days.
There is no specific antidote to carprofen but general supportive therapy as applied to clinical overdose with NSAIDs should be applied.
ATCvet code: QM01AE91
Pharmacotherapeutic group: anti-inflammatory, NSAID, aryl proprionic acids
Carprofen is a non-steroidal anti-inflammatory drug (NSAID), of the 2-aryl propionic acid class and possesses anti-inflammatory, analgesic and antipyretic activities. The mechanism of action of carprofen, is not well known. However, it was shown that the inhibition of the cyclo-oxygenase enzyme by carprofen is relatively weak at the recommended dosage. Moreover, it was shown that carprofen doesn’t inhibit the generation of thromboxane (TX) B2 in dog clotting blood and neither prostaglandin (PG) E2 nor 12-hydroxyeicosatetraenoic acid (HETE) in inflammatory exudate are inhibited. This suggests the mechanism of action of carprofen is not the inhibition of the eicosanoids. Some authors suggested an activity of carprofen on one or numerous inflammatory mediators not yet identified but no clinical evidence could be shown.
Carprofen exists in two enantiomeric forms, R(-)-carprofen and S(+)-carprofen and the racemic form is the one marketed. Laboratory animal studies suggest that the S(+) enantiomer possesses greater anti-inflammatory potency.
Ulcerogenic potential of carprofen has been shown in the rodents but not in the dogs.
After a single oral administration of 4 mg of carprofen per kg of bodyweight in dog, the time to obtain a maximum plasmatic concentration of 23µg/ml is about 2 hours. The oral bioavailability is more than 90% of the total dose. Carprofen is more than 98% bound to plasma proteins and its volume of distribution is low.
Carprofen is excreted in the bile with 70 % of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate. Carprofen undergoes an enantioselective enterohepatic cycle in dog, with only the S(+) enantiomer being significantly recycled. The plasmatic clearance of the S(+) carprofen is about twice that of the R(-) carprofen. The biliary clearance of S(+) carprofen seems to be subject to stereoselectivity too as it is about three times higher than that of R(-) carprofen.
Pig liver flavour
Anhydrous colloidal silica,
Microcrystalline cellulose, Lactose monohydrate.
Shelf-life of the veterinary medicinal product as packaged for sale:
Shelf-life after first opening the immediate packaging:
Do not store above 30°C Protect from light.
Divided tablets should be stored in the blister pack. Any divided tablet portions remaining after 72 hours should be discarded.
Blister complex: PVDC-PVC/Aluminium heat sealed blisters with 6 tablets / blister.
Cardboard box with 2 blisters of 6 tablets.
Cardboard box with 20 blisters of 6 tablets.
Cardboard box with 40 blisters of 6 tablets.
Cardboard box with 80 blisters of 6 tablets.
Not all pack sizes may be marketed.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Ceva Animal Health Ltd
Unit 3, Anglo Office Park
White Lion Road
4 February 2010
10. DATE OF REVISION OF THE TEXT
Approved: 20 October 2016
Carprodyl® F tablets are scored, circular beige tablets containing as active ingredient 20 mg, 50 mg or 100 mg carprofen.
For analgesia and reduction of inflammation caused by musculo-skeletal disorders and degenerative joint disease of the dog. Carprodyl® F tablets can also be used as a follow-up to parenteral analgesia in the management of post-operative pain in dogs.
For oral administration. The tablets are flavoured and are readily consumed by most dogs when offered. An initial dose of 4 mg carprofen/kg bodyweight/day is recommended to be given as a single dose or in two equally divided doses. Subject to clinical response the dose may be reduced. To extend analgesic and anti-inflammatory cover post operatively, parenteral therapy with carprofen injection may be followed with carprofen tablets at 4mg/kg/day for up to 5 days.
Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision. Do not exceed stated dose.
The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. Consequently, do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in cases of known hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not use in puppies less than 4 months of age.
Special precautions for use in animals
Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Do not administer other NSAIDs concurrently or within 24 hours. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Response to long-term treatment should be monitored at regular intervals by a veterinary surgeon.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.
Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. Rare cases of gastrointestinal bleeding are reported. If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought. As with other NSAIDs there is a rare risk of renal or idiosyncratic hepatic adverse events.
No signs of toxicity appeared when dogs were treated with carprofen at levels up to 6 mg/kg twice daily for 7 days (3 times the recommended dose rate of 4 mg/kg) and 6 mg/kg once daily for a further 7 days (1.5 times the recommended dose rate of 4 mg/kg). There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs, should be given. Due to the flavourings in the tablets, store in a secure location. Severe adverse reactions may occur if large quantities are ingested. If you suspect that your dog has consumed tablets above the labelled dose, contact your veterinarian.
Interaction with other medicinal products and other forms of interaction
Carprofen must not be administered with glucocorticoids.
For animal treatment only. Keep out of reach and sight of children.
This medicinal product does not require any special temperature storage conditions
Store tablets and half-tablets in the original blister in order to protect from light.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Box containing 2 blisters of 10 tablets
Box containing 10 blisters of 10 tablets
Box containing 20 blisters of 10 tablets
Box containing 50 blisters of 10 tablets
Not all pack sizes may be marketed.
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) of the 2-aryl propionic acid class and possesses anti-inflammatory, analgesic and antipyretic activities.
The mechanism of action of carprofen, like other NSAIDs, is believed to be associated with the inhibition of cyclo-oxygenase activity.
Two unique cyclo-oxygenases have been described in mammals. The constitutive cyclo-oxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclo-oxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. In an in-vitro study, using canine cell cultures, carprofen demonstrated selective inhibition of COX-2 versus COX-1. Clinical relevance of these data has not be shown.
Carprofen has also been shown to inhibit the release of several prostaglandins in two inflammatory cell systems: rat polymorphonuclear leukocytes (PMN) and human rheumatoid synovial cells, indicating inhibition of acute (PMN system) and chronic (synovial cell system) inflammatory reactions.
Several studies have demonstrated that carprofen has modulatory effects on both humoral and cellular immune responses. Carprofen also inhibits the production of osteoclast-activating factor (OAF), PGE1 and PGE2 by its inhibitory effect on prostaglandin biosynthesis.
After oral administration, carprofen is well absorbed in the dogs. Following the administration of the product tablets in dogs, a mean Cmax (maximum concentration in serum) of 6.1 mg/L and 3.6 mg/L was achieved at approximately 1 hour for Carprofen R(-) and Carprofen S(+), respectively. For both enantiomers, the mean half-life was approximately 9 hours. The analgesic effect from each dose persists for at least 12 hours.
Carprofen has a small volume of distribution and a low systemic clearance. It is highly bound to plasma protein. Carprofen is metabolised in the liver by conjugation and oxidation. The excretion of the glucuronide conjugate is mainly faecal after biliary excretion.
Carprodyl® F 20 mg - Vm 15052/4033
Carprodyl® F 50 mg - Vm 15052/4034
Carprodyl® F 100 mg - Vm 15052/4035
Carprodyl F 100mg:
Carprodyl F 50mg:
Carprodyl F 20mg:
All prices include VAT where applicable.
There are currently no questions for Carprodyl Quadri - be the first to ask one!Ask A Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.